BlossomHill Therapeutics, Inc. (BLSM) Stock Price & Analysis
BlossomHill Therapeutics, Inc. (BLSM) is trading at USD 14.7, down 2.84% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.
BLSM last closed at USD 14.7; today's session has ranged USD 14.34–16.75 on volume of 242,333 shares. Market capitalization is —, with a 52-week range of USD 11.02–27.99 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BLSM.md
Key facts (BLSM)
- Insider open-market purchases, last ~7 months: 4 Form 4 filings, $5.2M; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -8.1% vs S&P 500 +11.9%; 5Y -8.1% vs S&P 500 +66.7%.
- Latest earnings report: 2026-11-12 (next date not yet announced).
- Dividend: BLSM paid no cash dividend in the last five years.
- Short interest: 590,133 shares (as of 2026-10-30), 3.7 days to cover.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (BLSM)
Insider purchases (SEC Form 4, open-market, last ~7 months) (BLSM)
4 purchases, $5.2M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-10 | Schmid John P. | Director | 6,000 | $96K | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-10 | Chen Bihua | Director | 312,500 | $5.0M | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-10 | Keyes Jason A | Chief Financial Officer | 700 | $11K | 16 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-07…2026-08-10 | Liptak Vincent Paul | General Counsel | 4,700 | $75K | 15.89 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BLSM)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-21 | Leerink Partners | Target raised | Outperform | $36 → $40 |
| 2026-09-21 | Guggenheim | Target raised | Buy | $30 → $40 |
| 2026-09-01 | LifeSci Capital | Initiated | Outperform | $32 |
| 2026-09-01 | Leerink Partners | Initiated | Outperform | $36 |
| 2026-09-01 | JP Morgan | Initiated | Overweight | $28 |
| 2026-09-01 | Guggenheim | Initiated | Buy | $30 |
| 2026-09-01 | HC Wainwright & Co. | Initiated | Buy | $35 |
Total return (dividends reinvested) (BLSM)
| 1Y (from 2026-08-07) | 5Y (from 2026-08-03) | |
|---|---|---|
| Total return | -8.1% | -8.1% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | — | — |
| Volatility (annualized) | 101.0% | 91.7% |
| Max drawdown | -54.0% (Sep 2026→Nov 2026) | -47.5% (Sep 2026→Nov 2026) |
Dividends (BLSM)
BLSM paid no cash dividend in the last five years.
Short interest (BLSM)
590,133 shares sold short, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 473,807 shares (+24.6%). Days to cover: 3.7 (short shares ÷ average daily volume).
BLSM major shareholder filing: Schedule 13D, Aug 18, 2026
ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC filed a Schedule 13D with the SEC on Aug 18, 2026, reporting up to 8.90% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. …
Source: SEC EDGAR, Schedule 13D filed Aug 18, 2026. Quoted word for word; Nexqual adds no interpretation.
BLSM earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Sep 30, 2026 | −$1.29 | −$0.90 | Miss −43.3% | — |
| — | Quarter ended Jun 30, 2026 | −$8.75 | −$0.77 | Miss −1036.4% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
BLSM recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | Schedule 13G | Jingrong Jean Cui, Yishan Li: 12.5% of shares, passive 5%+ holder |
| Nov 16, 2026 | Schedule 13G | JANUS HENDERSON GROUP Ltd.: 7.8% of shares, passive 5%+ holder |
| Nov 16, 2026 | Schedule 13G/A | Vivo Innovation Fund II Holdings, L.P., Vivo Innovation II, LLC: 4.7% of shares, passive 5%+ holder (amended) |
| Nov 12, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 12, 2026 | 8-K | Quarterly results |
| Sep 18, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Sep 18, 2026 | 8-K | Quarterly results |
| Sep 15, 2026 | 8-K | Regulation FD disclosure |
| Aug 18, 2026 | Schedule 13D | ORBIMED ADVISORS LLC, OrbiMed Capital GP VIII LLC: 8.9% of shares, 5%+ holder that may seek to influence the company “This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business…” |
| Aug 17, 2026 | Schedule 13G | Vivo Innovation Fund II Holdings, L.P., Vivo Innovation II, LLC: 5.5% of shares, passive 5%+ holder |
| Aug 14, 2026 | Schedule 13G | Perceptive Advisors LLC, Joseph Edelman: 5.9% of shares, passive 5%+ holder |
| Aug 13, 2026 | Schedule 13D | Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC: 11.8% of shares, 5%+ holder that may seek to influence the company “The Reporting Persons acquired the securities reported herein for the benefit of the above-referenced private investment funds and accounts for investment purposes. The Reporting Persons intend to evaluate this investment in the Issuer and options with respect to such investment…” |
| Aug 10, 2026 | 8-K | Bylaws or fiscal-year change; Other material event “On August 10, 2026, the Company completed its IPO of an aggregate of 9,375,000 shares of common stock at a price to the public of $16.00 per share. The aggregate gross proceeds from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $150.0 million.” |
| Aug 3, 2026 | S-1/A | Registration of new shares |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
BLSM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-0.81 | $0.00 | −$0.81 | $0 | 1 |
| Next quarter (ends Mar 2027) | $-1.01 | $0.00 | −$1.01 | $0 | 1 |
| Current fiscal year (ends Dec 2026) | $-6.80 | $0.00 | −$6.80 | $0 | 1 |
| Next fiscal year (ends Dec 2027) | $-3.90 | $0.00 | −$3.90 | $0 | 2 |
Key Statistics (as of November 18, 2026 at 20:43 UTC)
| Price | USD 14.7 |
|---|---|
| Change | ▼ 2.84% (down) |
| Previous Close | USD 14.7 |
| Open | USD 14.7 |
| Day Range | USD 14.34 – 16.75 |
| 52-Week Range | USD 11.02 – 27.99 |
| Volume | 242,333 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (BLSM)
Nexqual's technical model rates BLSM "SELL" based on 1 bullish and 4 bearish signals across 73 daily candles, as of November 18, 2026 at 20:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.02 (neutral) |
| vs SMA50 | Below (USD 17.54) |
| MACD | -0.59 (negative) |
Earnings (BLSM)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.81 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -1.29 vs est -0.9 ▼ miss |
| 2026-06-30 | USD -8.75 vs est -0.77 ▼ miss |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financials & Fundamentals (BLSM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.11 |
| Current Ratio | 12.82 |
| Total Cash | $224.90M |
| Total Debt | $23.10M |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financial Health Score (BLSM)
Nexqual rates BlossomHill Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $225M cash vs $23M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (BLSM)
| Insider Ownership | +12.71% |
|---|---|
| Institutional Ownership | +53.30% |
| Shares Outstanding | 31.78M |
| Float | 17.63M |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 98.14 | ▲ 1.38% |
| BLTE | Belite Bio, Inc | USD 157.14 | ▼ 0.37% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.92 | ▼ 0.42% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.19% |
| IMVT | Immunovant, Inc. | USD 33.3 | ▲ 0.27% |
| CGON | CG Oncology, Inc. | USD 79.9 | ▲ 1.22% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt